Artificial intelligence, digital health and novel therapeutic technologies are expected to drive transformation in biopharma in 2024, despite ongoing challenges in financing.
In Vivo has selected 20 voices from among several hundred industry leaders and experts who responded to sister publication Scrip‘s...